The multiple‐kinase inhibitor lenvatinib inhibits the proliferation of acute myeloid leukemia cells

BACKGROUND: Current chemotherapy for acute myeloid leukemia (AML) mainly involves cytotoxic agents such as doxorubicin (DNR), mitoxantrone (Mito) or 2‐aminopurine‐6‐thiol (6‐TG). However, because these agents are relatively ineffective, discovering other more effective drugs for AML treatment would...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Fan, Li, Xiaojuan, Li, Ruisheng, Li, Boan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762047/
https://www.ncbi.nlm.nih.gov/pubmed/31773093
http://dx.doi.org/10.1002/ame2.12076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762047/
https://www.ncbi.nlm.nih.gov/pubmed/31773093
http://dx.doi.org/10.1002/ame2.12076

Ejemplares similares